Evoke Wealth’s PhenomeX Inc. Common Stock CELL Stock Holding History

Evoke Wealth’s Portfolio CELL Stock Details CELL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-800	Closed	-$6K	–	1269
2022 Q1	$6K	Hold	800	–	–	﹤0.01%	888
2021 Q4	$15K	Buy	800 +300	+60%	+$6.47K	﹤0.01%	727
2021 Q3	$9K	Hold	500	–	–	﹤0.01%	766
2021 Q2	$22K	Buy	+500	New	+$23.2K	﹤0.01%	643

Other funds holding CELL

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Evoke Wealth's CELL Position: Q2 2022 in Review

Evoke Wealth sold out of PhenomeX Inc. Common Stock (CELL) in Q2 2022, closing a stake of 800 shares — an estimated $6K sold.

Evoke Wealth first reported a position in CELL in Q2 2021 and held it in 4 quarters. The position peaked at $22K in Q2 2021. 123 funds tracked by Wall St. Rank hold CELL as of Q2 2022.

Evoke Wealth reported no remaining PhenomeX Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Evoke Wealth sold 800 PhenomeX Inc. Common Stock shares in Q2 2022, an estimated $6K.
Evoke Wealth first reported a position in PhenomeX Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Evoke Wealth's PhenomeX Inc. Common Stock position peaked at $22K in Q2 2021.
123 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q2 2022.

Based on Evoke Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.